RxDoctor Payments Data

John Loftus, MD

Vascular Surgery · Napa, CANPI 1922074319

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,400 of the $8,943 with a category attached, or 71.6%. Medtronic accounts for 81.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $6,637 and has fallen 96.5% since, to $233 in 2025.

$8,943in general payments, 2019–2025

Across 49 payments — averaging $182.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Penumbra, Inc.$1K
  • Shockwave Medical, Inc$214
  • Osiris Therapeutics Inc.$121
  • Boston Scientific$41
  • Intuitive Surgical$39
  • plus $73 from 4 others
$45,177in research payments, 2019–2025

Across 5 payments — averaging $9035.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avita Medical Americas, LLC$45K

What the payments were for

  • Travel & lodging$6,40072%
  • Food & beverage$2,54328%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,943 in reported general payments places this provider in the 65th percentile of 519 vascular surgery providers in California.

See all vascular surgery providers in California

Medicare billing

Part B allowed, 2024
$314,342
Medicare patients
508
Services billed
1,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate35$422
Cilostazol31$273
Tramadol Hcl71$164

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →